Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-high trading volume on Thursday . Approximately 1,779,641 shares were traded during mid-day trading, an increase of 244% from the previous session’s volume of 517,172 shares.The stock last traded at $3.5050 and had previously closed at $3.46.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IVA shares. Truist Financial initiated coverage on shares of Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $16.56.

Inventiva Trading Up 1.3%

The company has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $5.35.

Inventiva (NASDAQ:IVA) last released its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. On average, equities analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently bought and sold shares of IVA. Creative Planning bought a new stake in shares of Inventiva during the 2nd quarter valued at $32,000. Virtu Financial LLC bought a new position in shares of Inventiva in the 4th quarter worth $60,000. XTX Topco Ltd bought a new position in shares of Inventiva in the 4th quarter worth $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the third quarter worth $116,000. Finally, Cerity Partners LLC bought a new stake in Inventiva in the fourth quarter valued at about $93,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.